Print this page    •   Back to Web version of article

News Flash!! Once-a-Day Triple NRTI Warning

October 27, 2003

Gilead Sciences, Inc., the manufacturer of the anti-HIV medication Tenofovir (Viread) today issued a "Dear Health Care Professional" letter (click here to view) describing high rates of virologic failure in patients treated with a "once-a-day" triple NRTI regimen that contains: Didanosine (ddI, Videx EC), Lamivudine (3TC, Epivir), and Tenofovir (Viread). This letter is somewhat technical and difficult to understand. Please call Roberto González at 206-957-1659 or 1-888-399-7837 if you would like further explanation.

Back to the STEP Ezine Volume 1, Issue 51 contents page.

This article was provided by Seattle Treatment Education Project. It is a part of the publication STEP Ezine. You can find this article online by typing this address into your Web browser:

General Disclaimer: is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.